KR102629654B1 - 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법 - Google Patents

아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법 Download PDF

Info

Publication number
KR102629654B1
KR102629654B1 KR1020180044850A KR20180044850A KR102629654B1 KR 102629654 B1 KR102629654 B1 KR 102629654B1 KR 1020180044850 A KR1020180044850 A KR 1020180044850A KR 20180044850 A KR20180044850 A KR 20180044850A KR 102629654 B1 KR102629654 B1 KR 102629654B1
Authority
KR
South Korea
Prior art keywords
crystalline form
acid salt
mesylic acid
formula
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180044850A
Other languages
English (en)
Korean (ko)
Other versions
KR20180118535A (ko
Inventor
오상호
김종균
오세웅
한태동
정수용
이성란
김경배
이영성
신우섭
주현
강정기
박수민
김동균
Original Assignee
주식회사유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102629654(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 주식회사유한양행 filed Critical 주식회사유한양행
Publication of KR20180118535A publication Critical patent/KR20180118535A/ko
Priority to KR1020230184208A priority Critical patent/KR102835717B1/ko
Application granted granted Critical
Publication of KR102629654B1 publication Critical patent/KR102629654B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020180044850A 2017-04-21 2018-04-18 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법 Active KR102629654B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020230184208A KR102835717B1 (ko) 2017-04-21 2023-12-18 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21
KR1020170051687 2017-04-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020230184208A Division KR102835717B1 (ko) 2017-04-21 2023-12-18 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법

Publications (2)

Publication Number Publication Date
KR20180118535A KR20180118535A (ko) 2018-10-31
KR102629654B1 true KR102629654B1 (ko) 2024-01-29

Family

ID=63857137

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020180044850A Active KR102629654B1 (ko) 2017-04-21 2018-04-18 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법
KR1020230184208A Active KR102835717B1 (ko) 2017-04-21 2023-12-18 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법
KR1020250093917A Pending KR20250111074A (ko) 2017-04-21 2025-07-11 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020230184208A Active KR102835717B1 (ko) 2017-04-21 2023-12-18 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법
KR1020250093917A Pending KR20250111074A (ko) 2017-04-21 2025-07-11 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법

Country Status (22)

Country Link
US (3) US11453656B2 (https=)
EP (1) EP3612529A4 (https=)
JP (2) JP7126514B2 (https=)
KR (3) KR102629654B1 (https=)
CN (1) CN110869367B (https=)
AR (1) AR111469A1 (https=)
AU (2) AU2018256227B2 (https=)
CA (1) CA3059543A1 (https=)
CO (1) CO2019011578A2 (https=)
EA (1) EA201992501A1 (https=)
IL (2) IL294666B2 (https=)
MA (1) MA49696A (https=)
MX (2) MX392634B (https=)
MY (1) MY201919A (https=)
NZ (1) NZ758443A (https=)
PH (1) PH12019502370A1 (https=)
SA (1) SA519410342B1 (https=)
SG (1) SG11201909615YA (https=)
TW (1) TWI776882B (https=)
UA (1) UA124364C2 (https=)
WO (1) WO2018194356A1 (https=)
ZA (1) ZA201907687B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
SG11201913517UA (en) 2017-07-28 2020-02-27 Yuhan Corp Improved process for preparing aminopyrimidine derivatives
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
WO2020125391A1 (zh) * 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
MX2021013955A (es) * 2019-05-14 2022-03-11 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación.
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
US12138351B2 (en) * 2020-04-14 2024-11-12 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
AU2024337472A1 (en) 2023-09-05 2026-04-16 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102076A1 (en) * 2014-10-13 2016-04-14 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100804566B1 (ko) 2003-12-25 2008-02-20 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법
DK1720853T3 (en) 2004-02-11 2016-03-29 Natco Pharma Ltd HIS UNKNOWN POLYMORPH FORM OF IMATINIBMYLYLATE AND PROCEDURE FOR PREPARING IT
NZ603525A (en) * 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
EA024729B1 (ru) * 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
WO2015003571A1 (zh) 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102076A1 (en) * 2014-10-13 2016-04-14 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities

Also Published As

Publication number Publication date
KR102835717B1 (ko) 2025-07-18
AU2022203486A1 (en) 2022-06-09
AR111469A1 (es) 2019-07-17
EA201992501A1 (ru) 2020-02-18
CA3059543A1 (en) 2018-10-25
CO2019011578A2 (es) 2020-02-28
CN110869367B (zh) 2023-09-15
TW201841910A (zh) 2018-12-01
SG11201909615YA (en) 2019-11-28
IL294666B2 (en) 2024-05-01
EP3612529A4 (en) 2020-11-18
KR20230175161A (ko) 2023-12-29
EP3612529A1 (en) 2020-02-26
WO2018194356A1 (en) 2018-10-25
AU2018256227A1 (en) 2019-10-31
CN110869367A (zh) 2020-03-06
US20230021395A1 (en) 2023-01-26
PH12019502370A1 (en) 2020-07-13
JP2020517611A (ja) 2020-06-18
KR20250111074A (ko) 2025-07-22
US11453656B2 (en) 2022-09-27
AU2022203486B2 (en) 2024-06-06
JP7390444B2 (ja) 2023-12-01
IL270018A (https=) 2019-12-31
NZ758443A (en) 2023-03-31
IL294666B1 (en) 2024-01-01
IL294666A (en) 2022-09-01
MY201919A (en) 2024-03-23
SA519410342B1 (ar) 2023-02-09
ZA201907687B (en) 2023-04-26
US11981659B2 (en) 2024-05-14
US12428401B2 (en) 2025-09-30
JP7126514B2 (ja) 2022-08-26
KR20180118535A (ko) 2018-10-31
JP2022166179A (ja) 2022-11-01
TWI776882B (zh) 2022-09-11
BR112019021868A2 (pt) 2020-05-26
US20210139461A1 (en) 2021-05-13
MX2022006357A (es) 2022-06-23
MX392634B (es) 2025-03-24
US20240279203A1 (en) 2024-08-22
UA124364C2 (uk) 2021-09-01
AU2018256227B2 (en) 2022-03-03
MA49696A (fr) 2020-06-03
IL270018B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
KR102835717B1 (ko) 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법
EP4421069B1 (en) Compounds and compositions for modulating egfr mutant kinase activities
US9650386B2 (en) Quinoline-substituted compound
US10906901B2 (en) Crystal form and salt form of N-phenyl-2-aminopyrimidine compound, and preparation method therefor
AU2022312332B2 (en) Novel pyrimidine-2,4-diamine derivatives, preparation method therefor, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
EA041089B1 (ru) Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения
HK40025158A (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
HK40025158B (zh) 氨基吡啶衍生物化合物的盐、其结晶形式、以及用於制备它们的方法
RU2831452C2 (ru) Новые производные пиримидин-2,4-диамина, способ их получения и фармацевтическая композиция, содержащая их в качестве активного ингредиента, для профилактики или лечения рака
BR112019021868B1 (pt) Sal de mesilato de n-(5-(4-(4-((dimetilamino)metil)-3- fenil-1h-pirazol-1-il) pirimidina-2-ilamino)-4-metóxi-2- morfolinofenil)acrilamida, seu processo de preparação, seus usos, e composição farmacêutica
CN117794914A (zh) 新型嘧啶-2，4-二胺衍生物、其制备方法及包含其作为活性成分的用于预防或治疗癌症的药物组合物

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601